Insurance red tape may delay skin cancer surgery, new study warns

NCT ID NCT07215988

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 70 skin cancer patients to see how long it takes to get insurance approval for off-label neoadjuvant therapy (treatment before surgery). Researchers will measure approval times, out-of-pocket costs, and whether delays lead to worse surgical outcomes. The goal is to understand how insurance hurdles affect care for people with advanced skin cancers like Merkel cell carcinoma and melanoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could highlight ways to speed up insurance approvals for off-label skin cancer treatments, potentially improving patient outcomes.
What could go wrong
This is an observational study, not a treatment trial. It only measures delays and costs, so it won't directly test if off-label treatments work better or worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE II CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.